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Abstract: Current treatment options for visceral leishmaniasis have several drawbacks, and clinicians
are confronted with an increasing number of treatment failures. To overcome this, the Drugs for
Neglected Diseases initiative (DNDi) has invested in the development of novel antileishmanial leads,
including a very promising class of oxaboroles. The mode of action/resistance of this series to
Leishmania is still unknown and may be important for its further development and implementation.
Repeated in vivo drug exposure and an in vitro selection procedure on both extracellular promastig-
ote and intracellular amastigote stages were both unable to select for resistance. The use of specific
inhibitors for ABC-transporters could not demonstrate the putative involvement of efflux pumps.
Selection experiments and inhibitor studies, therefore, suggest that resistance to oxaboroles may not
emerge readily in the field. The selection of a genome-wide cosmid library coupled to next-generation
sequencing (Cos-seq) was used to identify resistance determinants and putative targets. This resulted
in the identification of a highly enriched cosmid, harboring genes of chromosome 2 that confer a
subtly increased resistance to the oxaboroles tested. Moderately enriched cosmids encompassing
a region of chromosome 34 contained the cleavage and polyadenylation specificity factor (cpsf ) gene,
encoding the molecular target of several related benzoxaboroles in other organisms.
Keywords: Leishmania; ABC transporters; oxaboroles; resistance
1. Introduction
Visceral leishmaniasis (VL) is a disease caused by an infection with the protozoan
parasites Leishmania infantum or L. donovani and results, among other symptoms, in seri-
ous anemia, wasting and hepatosplenomegaly, which can eventually be fatal when left
untreated [1]. The Leishmania parasite is transmitted to humans by sandflies, following es-
tablishment and differentiation into infective stages in the insect gut [2,3]. In the vertebrate
host, parasites infect and replicate inside mononuclear phagocytic cells [4], from where
they further disperse to the main target organs: the liver, spleen and bone marrow [5].
The disease is treated with a number of drugs that have disadvantages, such as the need
for hospitalization, high cost, toxicity, and the emergence of treatment failure [6]. It is
for that reason that the Drugs for Neglected Diseases initiative (DNDi) has invested in
the development of novel antileishmanial drugs, with the recent discovery of promising
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preclinical leads and clinical candidates [7,8]. One of the most promising lead series is the
oxaboroles, with DNDI-6148 as the frontrunner, currently in Phase I clinical trials [9,10].
Benzoxaboroles belong to a versatile class of drugs used to treat a wide variety
of diseases with low intrinsic toxicity [11]. A viral protease [12], beta-lactamase and
leucyl tRNA synthetase (LeuRS) are examples of targets for oxaboroles that have been
identified in viruses, bacteria and fungi [13–18]. The inhibition of fungal LeuRS relies
on the ability of benzoxaboroles to form adducts with the cis-diol moieties of sugars,
resulting in a stable tRNALeu-benzoxaborole adduct [19]. AN2690, also known as tavabo-
role, is an FDA-approved example of a benzoxaborole with broad-spectrum antifungal
activity [11,20]. The mechanism of action (MoA) has already been evaluated against a
number of pathogens [12–16,21,22], including Trypanosoma spp. [23–27]. In T. brucei, the
cleavage and polyadenylation specificity factor 3 (CPSF3) was shown to be a benzoxabo-
role target [21–23,25]. Additionally, one study revealed that the benzoxaboroles needed
peptidase-activation for trypanocidal activity [27]. However, the MoA of DNDI-6148 and
related oxaboroles in Leishmania have yet to be determined.
Drug target identification in kinetoplastids can be achieved through multiple unbiased
techniques [28]. In the present study, DNDI-6148 was screened against two Leishmania
genome-wide, cosmid-based overexpression libraries. The principle behind this approach
is that overexpression of a drug target can result in resistance to the corresponding drug
by increasing the pool of functional protein. Cosmids containing fragments of Leishmania
genomic DNA that confer an advantage during compound selection are harvested and then
analyzed by next-generation sequencing [29,30]. This analysis allows the overexpressed
fragments driving the resistant phenotype to be identified. A frequently used alterna-
tive technique is the experimental selection of drug resistance, followed by comparative
whole-genome sequencing [28,31,32]. This strategy also provides some information on
the propensity toward resistance in clinical settings [33–35], which is an emerging issue
for almost all currently available antileishmanial drugs [33,34,36–39]. A resistant pheno-
type can be acquired in multiple ways, but a common mechanism is an overexpression
of ATP binding cassette (ABC) efflux transporters, including ABCB (MDR) and ABCC
(MRP) pumps [40,41]. In Leishmania, these pumps are implicated in reduced susceptibility
to miltefosine (MIL), antimony (Sb) and amphotericin B (AMB) [39,42–49]. Evaluating
whether novel compounds are substrates of these efflux pumps, therefore, provides some
indication about the emergence of resistance.
Resistance selection and the inhibition of efflux ABC transporters were used in this
study as experimental tools to evaluate the likelihood of resistance emergence. Cosmid se-
quencing supported the identification of resistance determinants, revealing the contribution
of genes on chromosome 2 to elevated resistance.
2. Materials and Methods
2.1. Parasite Cultures
Two laboratory strains, MHOM/MA/67/ITMAP263 (L. infantum) and MHOM/ET/67/
L82 (L. donovani), were routinely cultured at 25 ◦C in HOMEM (Gibco, Life Technologies)
supplemented with 10% inactivated bovine serum (iFBS) (Gibco, Life Technologies, Ghent,
Belgium). Ex vivo amastigotes of both strains were purified from the spleens of heavily in-
fected donor hamsters [34]. MHOM/FR/09/LEM4038 and MHOM/FR/96/LEM3323Cl4 are
two clinical isolates from HIV-infected patients and were only available as promastigotes [50].
2.2. Animals
Female Swiss mice and female golden hamsters were purchased from Janvier (Le
Genest-Saint-Isle, France) and kept in quarantine for at least 5 days before use. Food for
laboratory rodents (Carfil, Arendonk, Belgium) and drinking water were available ad
libitum. At the start of the in vivo experiments, hamsters were randomly allocated to
experimental units of 3 animals.
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2.3. Test Substances and Formulations
DNDI-6148 and DNDI-5421 (structures as published in [9]) were provided by DNDi
(Geneva, Switzerland), and stock solutions for in vitro assays (20 mM) were prepared
in 100% DMSO. Potassium antimonyl tartrate (SbIII) was purchased from Sigma-Aldrich
(Diegem, Belgium) and stock solutions were made in phosphate-buffered saline (PBS) at
5.12 mg/mL. The efflux pump inhibitors verapamil, cyclosporine and probenecid were
purchased from Sigma-Aldrich and were formulated in 100% DMSO at 20 mM, except for
probenecid, which was diluted up to 50 mM in PBS after the addition of ethanol (2%) and
NaOH. Dilution series from the stock solutions were prepared in demineralized water to
ascertain a < 1% final in-test concentration of DMSO. For the in vivo experiments, DNDI-
6148 was prepared at 12.5 mg/mL in 2% ethanol, followed by the addition of 1N NaOH
(1.0 eq.) and then further diluted in 5% dextrose in water.
2.4. Intracellular Amastigote Susceptibility Assay
Forty-eight hours prior to peritoneal macrophage collection, mice were stimulated by
an intraperitoneal (IP) injection of 1 mL 0.2% starch suspension in PBS. After euthanasia
with a CO2 overdose, macrophages were collected by intraperitoneal lavage with 10 mL of
RPMI-1640 (Life Technologies). After counting in a KOVA® chamber, 3 × 104 cells/well
were seeded into a 96-well plate in 100 µL of RPMI-1640 macrophage medium, supple-
mented with 5% iFBS, 2% penicillin/streptomycin and 1% L-glutamine. Macrophages were
infected 24 h later with metacyclic promastigotes at a 15:1 multiplicity of infection and
incubated at 37 ◦C and 5% CO2 for another 24 h. Next, the culture medium was removed by
flicking the plate to eliminate remaining extracellular promastigotes and fresh medium and
the drug dilutions were added to the wells. Drug exposure was for a 96 h period without
renewal of the medium. Plates were fixated with methanol and stained with Giemsa for
microscopic evaluation and EC50 determination.
2.5. Promastigote Susceptibility Assay
Log-phase promastigotes (±72 h cultures) were counted and diluted to a concentration
of 105 promastigotes/well in a 96-well plate to which twofold dilutions of the test com-
pounds were added. Drug exposure was for a 72 h period without renewal of the culture
medium, after which, parasite proliferation was assessed using resazurin. Drug activity
was determined based on the percentage reduction in parasite proliferation compared to
the non-treated control wells.
2.6. In Vivo Resistance Selection
Resistance selection was performed as previously described by Hendrickx et al. [34].
Spleen-derived amastigotes of the L. infantum strain ITMAP263 were diluted in PBS to
prepare an infection inoculum containing 2 × 107 amastigotes in a total volume of 100 µL.
Oral treatment through gavage for 5 subsequent days started 21 days post-infection (dpi).
Upon relapse, amastigotes were collected from the spleen and used for the infection of new
hamsters. These treatment/relapse cycles were repeated for a maximum of 5 cycles. DNDI-
6148 was given at 25 mg/kg/day BID, which was shown to result in a > 98% amastigote
reduction in both liver and spleen [9].
2.7. In Vitro Intracellular Amastigote Resistance Selection
Intracellular amastigote resistance selection was performed as previously described
in Hendrickx et al. [33]. In brief, primary peritoneal mouse macrophages were infected
with either LEM4038 or ITMAP263 promastigotes in two duplicate 96-well plates and
exposed to increasing DNDI-6148 concentrations. One plate was used for Giemsa staining,
while the other plate was used for promastigote back-transformation (PBT). The latter
entails the release of residual viable amastigotes and allowing their transformation into
promastigotes in HOMEM medium at 25 ◦C. Promastigotes were recovered from the
highest drug exposure and further expanded in routine culture. This procedure of infection
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and PBT cycles was repeated until susceptibility decreased substantially, or for a maximum
of five successive passages.
2.8. In Vitro Extracellular Promastigote Resistance Selection
Log-phase promastigotes of LEM3323Cl4 were counted in a KOVA® counting chamber
and were diluted to a final concentration of 5 × 106 promastigotes in 5 mL HOMEM
containing the EC50 of the oxaboroles. The promastigotes were then left to recover from
drug exposure without renewal of the medium. Upon complete recovery, the promastigotes
were sub-cultured in a medium containing twice the drug concentration to initiate a next-
selection round. This procedure was repeated until the promastigotes could not withstand
a higher drug concentration. Finally, an extracellular susceptibility assay was performed to
assess the acquisition of resistance.
2.9. Intracellular Efflux Susceptibility Assay
Spleen-derived L. infantum ITMAP263 or L. donovani L82 amastigotes were used to
infect peritoneal mouse macrophages at a 5:1 infection ratio. The medium was replaced 2 h
later with fresh RPMI-1640 medium containing oxaborole and one of the ABC-transporter
inhibitors, namely, verapamil (MDR and MRP inhibitor), cyclosporine A (broad specificity
efflux inhibitor), or probenecid (MRP inhibitor). The ABC-transporter inhibitor was added
at a single concentration below its EC50 which was previously determined [51]; verapamil
was added at 8 µM, probenecid at 700 µM, and cyclosporine A at 1.5 µM for L. infantum
and 2 µM for L. donovani. A 4-fold dilution series was prepared for the oxaboroles with
the highest in-test concentration of 10 µM. SbIII was used as a reference compound for
validation of the assay. EC50-values with and without ABC-transporter inhibitor were
determined microscopically as described above for the intracellular amastigote assay and
the different conditions were compared.
2.10. Extracellular Efflux Susceptibility Assay
L. infantum and L. donovani log-phase promastigotes were diluted to a concentration of
106 promastigotes/well in a 96-well plate, whereafter dilutions of SbIII and oxaborole were
added either with or without the ABC-transporter inhibitor. Pump inhibitor concentrations
were previously determined and were identical to those in the intracellular assay [51].
EC50-values with and without ABC-transporter inhibitor were determined as described
above in the extracellular susceptibility assay and the different conditions were compared.
2.11. Cosmid Library Primary Screen (L. infantum)
L. infantum ITMAP263 promastigotes containing an empty cL-HYG vector were used
for initial susceptibility determination [52]. Cos-Seq was performed as previously described
by Gazanion et al. [29]. Briefly, L. infantum ITMAP263 promastigotes harboring a cL-
HYG genomic DNA library were exposed to the EC50 of DNDI-6148 in two biological
repeats. Parasite growth was followed up daily by spectrophotometry (λ = 600 nm)
until parasites reached the late log phase. At that time, part of the culture was diluted
and exposed to a higher drug concentration. The remaining culture was used for cosmid
extraction and further analysis. This procedure was repeated for several rounds of increased
drug exposure.
Cosmids were extracted from the parasites by SDS/alkali lysis followed by phe-
nol/chloroform extraction [53]. RNAse treatment was performed by a combination of
10 µg/mL ribonuclease A and 25 units/mL ribonuclease T1. A second phenol/chloroform
extraction allowed genomic DNA digestion with a Plasmid-Safe™ ATP-dependent DNase.
Finally, the kinetoplastid DNA was removed by separation on 1% low melting-point
agarose gel, followed by a gel extraction and purification of high-molecular-weight cosmid
DNA (>50 kb).
Paired-end libraries of each sample were prepared using 40 ng of extracted cosmid
DNA and the Nextera DNA sample preparation kit (Illumina, San Diego, CA, USA),
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following the manufacturer’s recommendations. The libraries were diluted to a final con-
centration of 8 pM and sequenced with the Illumina HiSeq 2500 system. Gene abundance
within samples was quantified using the Kallisto software. Clusters of genes that were
significantly enriched by drug selection were retrieved with edgeR using the default pa-
rameters (false discovery rate ≤ 0.001). Gene clusters were then plotted according to the
median-centered log2 fragment per kilobase per million mapped reads (FPKM) values, us-
ing R scripts included in the Trinity package. A first selection was made by only including
genes enriched with a log2-fold change of ≥4.
2.12. Cosmid Library Secondary Screen (L. donovani)
The second genome-wide cosmid-based library in L. donovani has been described
previously [30]. Briefly, the L. donovani library was maintained at a minimum concentration
of 3.33 × 105 cells/mL (1.5 × 107 cells in total) in the presence of 125 µg/mL Geneticin
(G418). DNDI-6148 was initially added to the library at a concentration equivalent to
2× the established EC50 value (500 nM) before being increased to 750 nM on day 4 of
selection. In total, the library was selected with DNDI-6148 for 11 days. At that point,
resistant cells were harvested, and cosmid DNA recovered and sequenced using an Illu-
mina HiSeq platform (Beijing Genomics Institute, Beijing, China). Sequence reads were
aligned to the L. donovani BPKLV9 genome sequence (v46.0, tritrypdb.org). Barcodes
flanking the genomic DNA inserts in enriched cosmids were identified with the following
sequences: 5′-GCGGCCGCTCTAGAACTAGT-3′ and 5′-CTCTTAAAAGCATCATGTCT-
3′ (for fragments in the sense direction) or 5′-ACTAGTTCTAGAGCGGCCGC-3′ and 5′-
AGACATGATGCTTTTAAGAG-3′ (for fragments in the anti-sense direction). All associated
datasets have been deposited with the European Nucleotide Archive under the following
accession number: PRJEB40932.
2.13. Cosmid Transfection and Impact on Drug Susceptibility
The cosmids identified from the primary screen were isolated by transfecting the
initially extracted pool of cosmids (which was used for sequencing) in high-efficiency
competent E. coli cells (NEB10). Random colony-picking then allowed the isolation of highly
enriched cosmids that were then sequenced for identification. Next, the isolated cosmids
of interest were transfected in L. infantum LEM3323Cl4. 2 × 108 cells were transfected with
10 µg cosmid DNA in a 0.4 cm gap cuvette (BioRad, Hercules, CA, USA) in cytomix buffer.
The cells were subjected to two consecutive pulses (10 s) at 1.5 kV, ∞ Ω resistance and 25 µF
capacitance, before they were transferred to HOMEM medium. Once parasites recovered
(24 h), they were exposed to 150 µg/mL hygromycin. Successfully transfected strains were
used for susceptibility testing as described above and for the generation of in vitro growth
curves under drug pressure.
RNA was extracted with the QIAamp RNA blood mini kit (Qiagen, Hilden, Ger-
many) from the wild-type strain and the transfected clones. An RT-qPCR was run in
duplicate using the one-step SensiFAST SYBR® Hi-ROX kit (Bioline) with primers spe-
cific for two genes within the cosmid; LINF_020008700 encoding for a putative protea-
some regulatory non-ATPase subunit 6 (primers: 5′-ACGTGAGCAACCTTCTGAGG-
3′ and 5′-GCAGCTTGCGATCGAGAATG-3′) and LINF_020008600 encoding for a pu-
tative casein kinase alpha chain (primers: 5′-GGATGCCTGTGTGTCCTCAA-3′ and 5′-
CAGCGAGCGTAGAATCTCGT-3′) (PCR settings: 1 cycle for 10′ at 45 ◦C and 2′ at 95 ◦C,
40 cycles for 5′′ at 95 ◦C and 20′′ at 60 ◦C, followed by a melt curve analysis with an
increment of 0.3 ◦C). The SL gene (Primers: 5′-AACTAACGCTATATAAGTAT-3′ and 5′-
CAATAAAGTACAGAAACTG-3′) was used as a reference gene for normalization (PCR
settings: 1 cycle for 10′ at 45 ◦C and 2′ at 95 ◦C, 40 cycles for 15′′ at 94 ◦C, 15′′ at 56 ◦C, 15′′
at 60 ◦C, followed by a melt curve analysis with an increment of 0.3 ◦C). The ∆∆Cq method
was used to calculate the relative normalized expression levels and to evaluate differential
expression between the different samples.
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Growth curves of the wild-type and transfected promastigotes (harboring an empty
or insert-carrying cosmid) were compared when exposed to 2 × EC50 and 5 × EC50 of
DNDI-6148. Promastigote clusters were first separated into single parasites by needle
passage (21G × 1 12 ′′, 0.8 × 40 mm, 25G × 5/8′′, 0.5 × 16 mm) and were then diluted in PBS
for flow cytometric (FCM) analysis using the MACSQuant flow cytometer (Miltenyi Biotec).
All FCM samples were analyzed in duplicate and further analyzed using the Flow Jo X
software. A growth curve was generated by following up the number of promastigotes
every 24 h for 7 days, starting with exactly 5 mL HOMEM with 5 × 105 promastigotes/mL.
2.14. Statistical Analysis
Susceptibility data and growth curves were analyzed using two-way analysis of
variance (ANOVA) and results were considered statistically significant if p was <0.05.
3. Results
3.1. In Vivo and In Vitro Intracellular Amastigote Resistance Selection
In vitro resistance selection for DNDI-6148 was found to be unsuccessful with intra-
cellular parasites, as susceptibility did not change significantly for either the L. infantum
LEM4038 field strain or the ITMAP263 lab strain (Table 1). For the latter, a small increase in
resistance index (RI) could be noted, up to a maximum of 2.5 after the first cycle; however,
this was unstable in the following cycles. Similarly, the in vivo resistance selection on
ITMAP263, which took approximately two years, did not result in a significantly decreased
susceptibility between the wild-type lines (2.95 ± 1.16 µM; 2.56 ± 1.03 µM; 2.57 ± 1.03 µM)
and 3 lines of ex vivo amastigotes collected after five successive passages (6.06 ± 2.90 µM;
4.93 ± 1.04 µM; 3.04 ± 0.07 µM).
Table 1. In vitro susceptibility of intracellular amastigotes to DNDI-6148 after each in vitro selection
cycle. Results are expressed as the mean EC50 (µM) ± standard mean of error (SEM) and are based
on two biological replicates, each consisting of two technical replicates.
ITMAP263 LEM4038
Wild Type 0.24 ± 0.20 0.51 ± 0.11
Cycle 1 0.61 ± 0.20 0.23 ± 0.08
Cycle 2 0.44 ± 0.20 0.21 ± 0.04
Cycle 3 0.48 ± 0.20 0.23 ± 0.06
Cycle 4 0.31 ± 0.04 0.29 ± 0.05
Cycle 5 0.44 ± 0.13 0.27 ± 0.06
3.2. DNDI-6148 Resistance Selection in Promastigotes
Resistance selection in the promastigote stage against the two selected oxaboroles was
found to be difficult and was halted after approximately 60 days. Drug exposure could
be increased in a stepwise fashion to a maximum of 2 µM for DNDI-6148 and 48 µM for
DNDI-5421 (Figure 1A). Higher drug concentrations led to irreversible growth inhibition
and ultimately parasite death. The stepwise selection did not result in a consistent increase
of the EC50, even though a slight increase could be observed at some passages with an
RI < 2 (Figure 1B,C).
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Figure 1. Overview of the stepwise generation of resistant parasite lines toward two oxaboroles (A). Comparison of the
in vitro susceptibility in the extracellular promastigote assay of the wild-type Scheme 6148 (B) and DNDI-5421 (C). Results
are expressed as the mean EC50 (µM) ± SEM, and are based on two biological replicates, each comprising two technical
replicates (* p < 0.05, *** p < 0.001).
3.3. The Involvement of Efflux Pumps
The reference compound SbIII was used to validate the assay, as its activity is known
to be affected by the ABC-transporter inhibitors verapamil and probenecid. No effects
were observed from co-incubating the oxaboroles with the efflux pump inhibitors in either
intracellular amastigote or promastigote susceptibility assays (Figure S1).
3.4. Screening of DNDI-6148 against a L. infantum Cosmid-Based Overexpression Library
An EC50 of 1.44 ± 0.30 µM was determined for DNDI-6148 on promastigotes of the
L. infantum ITMAP263 line transfected with a whole-genome cosmid library derived from
that strain. The transfected parasites could sustain exposure to DNDI-6148 at 1×, 1.5×
and up to 2 × IC50 (2.88 µM) (Figure 2A). It was not possible to further increase the drug
concentration, as parasites were unable to multiply at 4 × IC50.
After each selection step, cosmids were extracted from the selected strain and se-
quenced. Analysis revealed that four cosmids were enriched more than 100-fold (Figure 2B,
Table S1), with one of these cosmids maintaining a fragment of genomic DNA from chro-
mosome 2 (genomic position: 153,221–186,003) being the most enriched (>20,000-fold)
(Table 2). Among several other hits identified, a cosmid bearing a fragment of chromosome
34 was enriched by ~770-fold. While less enriched than the cosmid derived from chro-
mosome 2, this cosmid encodes for the cleavage and polyadenylation specificity factor (CPSF).
Several previous studies have identified CPSF as the molecular target of several related
benzoxaboroles in a variety of organisms. The role of this gene and DNDI-6148 MoA in
Leishmania is being pursued by Wyllie and other collaborators.
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Figure 2. Overview of the Cos-Seq L. infantum library selection and bio-analysis. (A) Growth curves of parasites transfected
with the cosmid library in the presence of increasing concentrations of DNDI-6148. Results are expressed as mean optical
density (OD) ± SEM, and are based on two biological repeats. (B) Normalized fold enrichment for the most highly enriched
cosmids after selection with DNDI-6148. The chromosomal and genomic locations of genomic DNA fragments maintained
by enriched cosmids are given.
Table 2. Overview of the gene functions of the isolated cosmid-harboring genes from chromosome 2.
Cosmid Gene ID Gene Function MaxEnrichment
Rationalised





family/UAA transporter family putative
33,225
LINF_020008500 Hypothetical protein conserved 25,936 LdBPK.02.2.000320.1
LINF_020008600 Casein kinase II—alpha chain putative 24,707 LdBPK.02.2.000330.1
LINF_020008700 Proteasome regulatory non-ATPasesubunit 6 putative 30,199 LdBPK.02.2.000340.1
LINF_020008800 FtsJ-like methyltransferase putative 22,404 LdBPK.02.2.000350.1
LINF_020008900 Ubiquitin-conjugating enzyme E2 putative 24,949 LdBPK.02.2.000360.1
LINF_020009100 Mitochondrial protein 81 1852
LINF_020009200 Hypothetical protein conserved 44,918
3.5. Screening of DNDI-6148 against a L. Donovani Cosmid-Based Overexpression Library
In order to rationalize the hits identified in the L. infantum cosmid library screen, DNDI-
6148 was screened against an equivalent L. donovani library [30]. The L. donovani cosmid-
based overexpression library was screened with DNDI-6148 at 750 nM for a total of 11 days,
until the selected population had a similar growth rate to the untreated control (Figure 3A).
Cosmids maintained by the “resistant” population were harvested and sequenced, and
enriched fragments were mapped to the L. donovani BPKLV9 genome. This analysis revealed
several fragments of the L. donovani genome that were enriched, albeit with relatively low
RPKM values (Figure 3B, Table S2). Interestingly, two genomic fragments enriched in
this library screen overlapped with “hits” identified in the L. infantum Cos-Seq screening
(Table S2). Specifically, a 62 kb region of chromosome 2 (genomic position 415,500–477,600;
Figure 3C) and a 61.5 kb region of chromosome 35 (genomic position 30,326,800–30,388,300;
Figure 3D) were identified that encompassed genomic fragments enriched in the primary
screen (Table 2). Using the barcodes from this second cosmid library screen, we were able
to rationalize these hits to five possible candidate genes on chromosome 2 (Figure 3C,
Table 2).
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Figure 3. Screen of L. donovani cosmid library with DNDI-6148. (A) Cumulative growth of the L. donovani library in the
presence (black circles) or absence (white circle) of DNDI-6148. Arrows indicate where the treated and untreated libraries
were passaged. (B) Genome-wide map indicating cosmid library hits from the screening of DNDI-6148. The top five hits
based on total reads are indicated. (C & D) Focus on two “hits” on chromosome 2 (C) and 35 (D), respectively. The genes
flanked by a majority of barcodes, and therefore most likely to be conferring resistance, are indicated in green, while other
genes are indicated in yellow. Possible genes (following a rationalization based on the location of barcodes) are shown
as green bars, other genes as yellow bars. The blue/pink and black/green peaks indicate independent cosmid inserts in
different orientations.
3.6. Validation
Since an overlapping fragment of chromosome 2 was enriched in both cosmid library
screens, we looked to validate the direct role of this genomic fragment, and the genes it
encodes, in resistance to DNDI-6148. Both DNDI-6148 and DNDI-5421 exert nanomolar
activity against the intracellular amastigote stage, confirming their potential use as ther-
apeutics. A susceptible strain of L. infantum (LEM3323Cl4) was transfected with either
the empty Cos-Seq cosmid or with the cosmid enriched 20,000-fold in the library screen.
Overexpression of the cosmid was confirmed using qPCR, where a 21.6 ± 1.6 fold and
a 21.8 ± 1.1 fold increase of expression was recorded for respectively the casein kinase
alpha chain and proteasome regulatory non-ATPase subunit 6 genes in LEM3323Cl4/CH2 com-
pared to the wild type. The expression of both genes in the strain harboring the empty
cosmid (LEM3323Cl4/CL) remained unchanged, with respectively 1.4 ± 0.1 and 1.5 ± 0.1
fold expression.
Promastigotes and amastigotes bearing the enriched cosmid (LEM3323Cl4/CH2)
demonstrated a modest decrease in susceptibility to the two oxaboroles tested compared to
those transfected with empty vector (Figure 4). Under drug pressure (2 × EC50), promastig-
otes harboring LEM3323Cl4/CH2 also demonstrated a clear growth advantage compared
to those harboring the empty cosmid (LEM3323Cl4/CL) (Figure 4E). Collectively, these
data confirm that elevated levels of the genes encoded on this fragment of chromosome
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2, and most likely their protein products, confer an advantage to parasites treated with
DNDI-6148 and DNDI-5421.
Figure 4. Susceptibility and growth curves of strains harboring either the empty cosmid (LEM3323Cl4/CL) or a cosmid
harboring genes from chromosome 2 (LEM3323Cl4/CH2), compared to the wild type (LEM3323Cl4). (A,B) Promastigote
and (C,D) amastigote susceptibility profiles against DNDI-6148 and DNDI-5421. The EC50 (A,C) and IC90 (B,D) are shown.
Results are expressed as the mean EC50/90 (µM) ± SEM and are based on at least two independent experiments with
biological duplicates. (E) In vitro growth curves of the strains exposed to DNDI-6148. Results are expressed as the mean
number of parasites/mL ± SEM, and are based on at least two independent experiments run in duplicate. A two-way
ANOVA test was performed to test significance (* p < 0.05, ** p < 0.01, *** p < 0.001).
4. Discussion
Screening a library of oxaborole compounds, followed by medicinal chemistry opti-
mization, led to the development of DNDI-6148, a promising antileishmanial compound
currently progressing through the various stages of preclinical drug development [9,10].
The MoA of several related oxaboroles has been studied in several pathogenic organisms,
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such as T. brucei, using untargeted metabolomics [20,54], chemoproteomics [21], whole-
genome knockdown (RNAi), and overexpression libraries [23,25], and via the selection of
drug-resistant parasites, followed by whole-genome sequencing (WGS) [20,21]. To date,
no equivalent studies have been carried out for oxaboroles demonstrating antileishma-
nial activity. Laboratory-selected resistance in Leishmania is often obtained by exposing
promastigotes and/or amastigotes stepwise to increasing concentrations of drug pres-
sure [28,34]. Although successful for other compounds, in vitro and in vivo resistance
selection procedures were unable to generate Leishmania clones resistant to our oxaborole
compounds. Additionally, the role of efflux pumps as a potential mechanism of resistance
to these compounds was evaluated using inhibitors of ABC-transporters such as verapamil,
cyclosporine A and probenecid [51,55–58]. These studies suggest that antileishmanial
oxaboroles are not substrates of the evaluated transporters, unlike several other antileish-
manials shown to be prone to efflux through these pumps [39,42–49]. Encouragingly, these
observations indicate that the oxaboroles studied here may not be prone to rapid resistance
development in the field.
In an attempt to identify the molecular target(s) of DNDI-6148 and/or resistance de-
terminants, this compound was used to screen two separate genome-wide, cosmid-based
Leishmania overexpression libraries. Both screens demonstrated that parasites bearing cos-
mids that harbored genes from chromosome 2 gained an advantage during selection with
DNDI-6148. Indeed, subsequent studies confirmed that promastigotes and amastigotes
transfected with cosmid LEM3323Cl4/CH2 were subtly resistant to DNDI-6148 and DNDI-
5421, as well as demonstrating a growth advantage under selection with both compounds.
The question remains as to which of the genes encoded on this specific fragment of
chromosome 2 is providing an advantage to parasites under pressure from DNDI-6148 and
DNDI-5421. Several of the genes present on the selected cosmids have the potential to play
a role in the tolerance of treatment with oxaboroles. Previous studies have demonstrated
the importance of several of the enriched genes for Leishmania survival and life-cycle
progression. The proteasome regulatory non-ATPase subunit is a crucial player in protein
recycling, vital for the survival and differentiation of kinetoplastids [59–63]. FtsJ-like
methyltransferase is generally important for protein biosynthesis [64,65]. In multiple
Leishmania spp., casein-kinase has been shown to be involved in stress resistance, growth
and infectivity [66–68]. Given the established functions of the proteins encoded by these
enriched genes, it is most likely that one of these plays an indirect role in increased tolerance
to oxaboroles, rather than representing their molecular target. Indeed, the mutation of
four different enzymes involved in ubiquitination and sumoylation has been observed in
Plasmodium parasites resistant to benzoxaborole AN13762 [69]. In this study, the mutation
of ubiquitination/sumoylation enzymes was thought to be a general response to changes
in the parasite stress response rather than an indication of specific drug targets. It is entirely
possible that amplification of the ubiquitin-conjugating enzyme E2 (chromosome 2) may
be playing the same role in DNDI-6148-treated Leishmania. Both cosmid screens pointed
to a region derived from chromosome 35 that is enriched in the presence of DNDi-6148.
There is an overlap of seven genes in the different cosmids (Tables S1 and S2), and one of
these genes may also provide a selective advantage in the presence of the drug.
CPSF, established as the molecular target of benzoxaboroles active against T. brucei and
several other parasites [25], was also identified as a hit in the Cos-Seq library, indicating
that the enzyme may also play a role in the mode of action of DNDI-6148 in Leishmania.
Drug targets are often the most enriched in Cos-seq screens [29]. As other genes were
found to be more enriched, it could be argued that CPSF, a 3′ end processing endonuclease,
may not be the primary target of oxaboroles in Leishmania. However, since this is a target
in other species, it is a likely candidate, and work to test it is ongoing in Dundee. It should
be noted that this enzyme functions as part of a complex that controls pre-mRNA cleavage,
polyadenylation, and transcription termination. Overexpression of a single component of
the complex without concomitant rises in the levels of other complex components may
significantly limit the levels of resistance achievable via this mechanism. Of course, another
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explanation for these observations is that antileishmanial oxaboroles might have multiple
targets. Further studies will be required to bring clarity to the issue.
In conclusion, our studies suggest that resistance to the promising antileishmanial
DNDI-6148 may not develop rapidly upon clinical use, since prolonged exposure to the
compound did not lead to the emergence of compound-resistant parasites. Furthermore,
DNDI-6148 and DNDI-5421 were confirmed not to be substrates of ABC-transporters, MDR
and MRP pumps, a common mechanism associated with resistance to several antileish-
manials. The screening of two separate cosmid-based overexpression libraries identified
an enriched cosmid, harboring genes from chromosome 2 that provide some advantage
under drug pressure. Formal identification of the Leishmania target(s) of DNDI-6148 and
additional resistance determinants will be important to the clinical development of this
compound, and possibly in selecting an appropriate partner drug for future combina-
tion therapy.
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and promastigote susceptibility assay. Table S1: Overview of the gene functions of the other highest
enriched cosmids from the L. infantum Cos-Seq screen. Table S2: Genes encoded by the top 5
enriched regions of cosmids in DNDI-6148-resistant parasites following selection of the counter-
screen cosmid library.
Author Contributions: Conceptualization, M.V.d.K., P.L., S.W., M.O., L.M. and G.C.; methodology,
M.V.d.K., P.L., D.M., S.H., L.B.T., R.J.W., S.W., M.O., L.M. and G.C.; formal analysis, M.V.d.K., P.L.,
R.J.W., S.W., M.O. and G.C.; investigation, M.V.d.K., P.L., D.M., S.H., L.B.T. and R.J.W.; resources, S.W.,
E.C., C.E.M., M.O., L.M. and G.C.; writing—original draft preparation, M.V.d.K.; writing—review
and editing, P.L., S.W., E.C., C.E.M., S.B., M.O., L.M. and G.C.; visualization, M.V.d.K., P.L., S.W., M.O.
and G.C.; supervision, S.W., M.O., L.M. and G.C.; project administration, S.W., E.C., C.E.M., M.O.,
L.M. and G.C.; funding acquisition, S.W., E.C., C.E.M., M.O., L.M. and G.C. All authors have read
and agreed to the published version of the manuscript.
Funding: This work was funded by the Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO,
G051812N and 12I0317N) and the University of Antwerp (TT-ZAPBOF 33049). This work was also
supported by a Canadian Institutes of Health Research Foundation Grant to M.O. M.O. holds
a Canada Research Chair in Antimicrobial Resistance. Work carried out at the University of
Dundee was supported by the following Wellcome Trust awards: [203134/Z/16/Z], [105021] and
[218448/Z/19/Z]. For the work described in this paper, DNDi received financial support from the
following donors: the Dutch Ministry of Foreign Affairs (DGIS), the Netherlands, the Federal Ministry
of Education and Research (BMBF) through KfW, Germany and the Wellcome Trust, UK.
Institutional Review Board Statement: This study using laboratory rodents was carried out in strict
accordance to all mandatory guidelines (EU directives, including the Revised Directive 2010/63/EU
on the protection of Animals used for Scientific Purposes that came into force on 01/01/2013, and
the declaration of Helsinki in its latest version) and was approved by the ethical committee of the
University of Antwerp, Belgium (UA-ECD 2011–77, revised 2015).
Informed Consent Statement: Not applicable.
Data Availability Statement: Data is contained within the article or Supplementary Materials.
Acknowledgments: The authors would like to thank Laurence Lachaud (Centre Hospitalier Univer-
sitaire de Montpellier) for providing the two French clinical isolates used in the study. For supporting
its overall mission, DNDi also thanks UK aid, UK; Médecins sans Frontières (MSF) and the Swiss Agency
for Development and Cooperation (SDC), Switzerland. LMPH is a partner of the Excellence Centre
‘Infla-Med’ (https://www.uantwerpen.be/infla-med).
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
Microorganisms 2021, 9, 1408 13 of 15
References
1. Pace, D. Leishmaniasis. J. Infect. 2014, 69 (Suppl. 1), S10–S18. [CrossRef]
2. Maroli, M.; Feliciangeli, M.D.; Bichaud, L.; Charrel, R.N.; Gradoni, L. Phlebotomine sandflies and the spreading of leishmaniases
and other diseases of public health concern. Med. Vet. Entomol. 2013, 27, 123–147. [CrossRef]
3. Sacks, D.; Kamhawi, S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu. Rev. Microbiol.
2001, 55, 453–483. [CrossRef] [PubMed]
4. Hommel, M. Visceral leishmaniasis: Biology of the parasite. J. Infect. 1999, 39, 101–111. [CrossRef]
5. Wilson, M.E.; Sandor, M.; Blum, A.M.; Young, B.M.; Metwali, A.; Elliott, D.; Lynch, R.G.; Weinstock, J.V. Local suppression of IFN-
gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 1996, 156, 2231–2239.
6. Nagle, A.S.; Khare, S.; Kumar, A.B.; Supek, F.; Buchynskyy, A.; Mathison, C.J.; Chennamaneni, N.K.; Pendem, N.; Buckner, F.S.;
Gelb, M.H.; et al. Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem. Rev.
2014, 114, 11305–11347. [CrossRef]
7. Chatelain, E.; Ioset, J.R. Drug discovery and development for neglected diseases: The DNDi model. Drug Des. Dev. Ther. 2011,
5, 175–181. [CrossRef]
8. Alves, F.; Bilbe, G.; Blesson, S.; Goyal, V.; Monnerat, S.; Mowbray, C.; Muthoni Ouattara, G.; Pecoul, B.; Rijal, S.; Rode, J.; et al.
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clin. Microbiol. Rev. 2018, 31.
[CrossRef] [PubMed]
9. Van den Kerkhof, M.; Mabille, D.; Chatelain, E.; Mowbray, C.E.; Braillard, S.; Hendrickx, S.; Maes, L.; Caljon, G. In vitro and
in vivo pharmacodynamics of three novel antileishmanial lead series. Int. J. Parasitol. Drugs Drug Resist. 2018, 8, 81–86. [CrossRef]
[PubMed]
10. DNDi. R&D Portofolio Visceral Leishmaniasis. Available online: https://dndi.org/research-development/portfolio/dndi-6148/
(accessed on 12 August 2020).
11. Liu, C.T.; Tomsho, J.W.; Benkovic, S.J. The unique chemistry of benzoxaboroles: Current and emerging applications in biotechnol-
ogy and therapeutic treatments. Bioorgan. Med. Chem. 2014, 22, 4462–4473. [CrossRef]
12. Li, X.; Zhang, S.; Zhang, Y.K.; Liu, Y.; Ding, C.Z.; Zhou, Y.; Plattner, J.J.; Baker, S.J.; Bu, W.; Liu, L.; et al. Synthesis and SAR of
acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties. Bioorgan. Med. Chem. Lett. 2011, 21, 2048–2054.
[CrossRef] [PubMed]
13. Rock, F.L.; Mao, W.; Yaremchuk, A.; Tukalo, M.; Crepin, T.; Zhou, H.; Zhang, Y.K.; Hernandez, V.; Akama, T.; Baker, S.J.; et al.
An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007, 316, 1759–1761.
[CrossRef]
14. Hernandez, V.; Crepin, T.; Palencia, A.; Cusack, S.; Akama, T.; Baker, S.J.; Bu, W.; Feng, L.; Freund, Y.R.; Liu, L.; et al. Discovery
of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob. Agents Chemother. 2013,
57, 1394–1403. [CrossRef]
15. Xia, Y.; Cao, K.; Zhou, Y.; Alley, M.R.; Rock, F.; Mohan, M.; Meewan, M.; Baker, S.J.; Lux, S.; Ding, C.Z.; et al. Synthesis and SAR
of novel benzoxaboroles as a new class of beta-lactamase inhibitors. Bioorgan. Med. Chem. Lett. 2011, 21, 2533–2536. [CrossRef]
16. Hu, Q.H.; Liu, R.J.; Fang, Z.P.; Zhang, J.; Ding, Y.Y.; Tan, M.; Wang, M.; Pan, W.; Zhou, H.C.; Wang, E.D. Discovery of a potent
benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase. Sci. Rep. 2013, 3, 2475. [CrossRef] [PubMed]
17. Shapiro, A.B.; Gao, N.; Hajec, L.; McKinney, D.C. Time-dependent, reversible, oxaborole inhibition of Escherichia coli leucyl-tRNA
synthetase measured with a continuous fluorescence assay. Anal. Biochem. 2012, 431, 48–53. [CrossRef]
18. Gupta, A.K.; Versteeg, S.G. Tavaborole—A treatment for onychomycosis of the toenails. Expert Rev. Clin. Pharmacol. 2016,
9, 1145–1152. [CrossRef]
19. Baker, S.J.; Tomsho, J.W.; Benkovic, S.J. Boron-containing inhibitors of synthetases. Chem. Soc. Rev. 2011, 40, 4279–4285. [CrossRef]
[PubMed]
20. Jinna, S.; Finch, J. Spotlight on tavaborole for the treatment of onychomycosis. Drug Des. Devel. Ther. 2015, 9, 6185–6190.
[CrossRef]
21. Sonoiki, E.; Ng, C.L.; Lee, M.C.; Guo, D.; Zhang, Y.K.; Zhou, Y.; Alley, M.R.; Ahyong, V.; Sanz, L.M.; Lafuente-Monasterio,
M.J.; et al. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor
homologue. Nat. Commun. 2017, 8, 14574. [CrossRef] [PubMed]
22. Palencia, A.; Bougdour, A.; Brenier-Pinchart, M.P.; Touquet, B.; Bertini, R.L.; Sensi, C.; Gay, G.; Vollaire, J.; Josserand, V.; Easom,
E.; et al. Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis. EMBO Mol. Med. 2017, 9, 385–394.
[CrossRef]
23. Begolo, D.; Vincent, I.M.; Giordani, F.; Pohner, I.; Witty, M.J.; Rowan, T.G.; Bengaly, Z.; Gillingwater, K.; Freund, Y.; Wade,
R.C.; et al. The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing. PLoS Pathog. 2018, 14, e1007315.
[CrossRef] [PubMed]
24. Jones, D.C.; Foth, B.J.; Urbaniak, M.D.; Patterson, S.; Ong, H.B.; Berriman, M.; Fairlamb, A.H. Genomic and Proteomic Studies on
the Mode of Action of Oxaboroles against the African Trypanosome. PLoS Negl. Trop. Dis. 2015, 9, e0004299. [CrossRef] [PubMed]
25. Wall, R.J.; Rico, E.; Lukac, I.; Zuccotto, F.; Elg, S.; Gilbert, I.H.; Freund, Y.; Alley, M.R.K.; Field, M.C.; Wyllie, S.; et al. Clinical and
veterinary trypanocidal benzoxaboroles target CPSF3. Proc. Natl. Acad. Sci. USA 2018, 115, 9616–9621. [CrossRef] [PubMed]
Microorganisms 2021, 9, 1408 14 of 15
26. Zhang, N.; Zoltner, M.; Leung, K.F.; Scullion, P.; Hutchinson, S.; Del Pino, R.C.; Vincent, I.M.; Zhang, Y.K.; Freund, Y.R.; Alley,
M.R.K.; et al. Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. PLoS Pathog. 2018,
14, e1006850. [CrossRef]
27. Giordani, F.; Paape, D.; Vincent, I.M.; Pountain, A.W.; Fernandez-Cortes, F.; Rico, E.; Zhang, N.; Morrison, L.J.; Freund, Y.; Witty,
M.J.; et al. Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. PLoS Pathog. 2020, 16, e1008932. [CrossRef]
28. Van den Kerkhof, M.; Sterckx, Y.G.; Leprohon, P.; Maes, L.; Caljon, G. Experimental Strategies to Explore Drug Action and
Resistance in Kinetoplastid Parasites. Microorganisms 2020, 8, 950. [CrossRef]
29. Gazanion, E.; Fernandez-Prada, C.; Papadopoulou, B.; Leprohon, P.; Ouellette, M. Cos-Seq for high-throughput identification of
drug target and resistance mechanisms in the protozoan parasite Leishmania. Proc. Natl. Acad. Sci. USA 2016, 113, E3012–E3021.
[CrossRef]
30. Corpas-Lopez, V.; Moniz, S.; Thomas, M.; Wall, R.J.; Torrie, L.S.; Zander-Dinse, D.; Tinti, M.; Brand, S.; Stojanovski, L.; Manthri,
S.; et al. Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infect. Dis. 2019,
5, 111–122. [CrossRef]
31. Berg, M.; Mannaert, A.; Vanaerschot, M.; Van Der Auwera, G.; Dujardin, J.C. (Post-) Genomic approaches to tackle drug resistance
in Leishmania. Parasitology 2013, 140, 1492–1505. [CrossRef]
32. Leprohon, P.; Fernandez-Prada, C.; Gazanion, E.; Monte-Neto, R.; Ouellette, M. Drug resistance analysis by next generation
sequencing in Leishmania. Int. J. Parasitol. Drugs Drug Resist. 2015, 5, 26–35. [CrossRef]
33. Hendrickx, S.; Boulet, G.; Mondelaers, A.; Dujardin, J.C.; Rijal, S.; Lachaud, L.; Cos, P.; Delputte, P.; Maes, L. Experimental
selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum. Parasitol.
Res. 2014, 113, 1875–1881. [CrossRef]
34. Hendrickx, S.; Mondelaers, A.; Eberhardt, E.; Delputte, P.; Cos, P.; Maes, L. In Vivo Selection of Paromomycin and Miltefosine
Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model. Antimicrob. Agents Chemother. 2015, 59, 4714–4718.
[CrossRef]
35. Hendrickx, S.; Mondelaers, A.; Eberhardt, E.; Lachaud, L.; Delputte, P.; Cos, P.; Maes, L. Intracellular amastigote replication may
not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum. Parasitol. Res. 2015, 114, 2561–2565.
[CrossRef] [PubMed]
36. Perry, M.R.; Prajapati, V.K.; Menten, J.; Raab, A.; Feldmann, J.; Chakraborti, D.; Sundar, S.; Fairlamb, A.H.; Boelaert, M.; Picado, A.
Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: A retrospective cohort
study. PLoS Negl. Trop. Dis. 2015, 9, e0003518. [CrossRef]
37. Srivastava, S.; Mishra, J.; Gupta, A.K.; Singh, A.; Shankar, P.; Singh, S. Laboratory confirmed miltefosine resistant cases of visceral
leishmaniasis from India. Parasites Vectors 2017, 10, 49. [CrossRef]
38. Cojean, S.; Houze, S.; Haouchine, D.; Huteau, F.; Lariven, S.; Hubert, V.; Michard, F.; Bories, C.; Pratlong, F.; Le Bras, J.; et al.
Leishmania resistance to miltefosine associated with genetic marker. Emerg. Infect. Dis. 2012, 18, 704–706. [CrossRef]
39. Purkait, B.; Kumar, A.; Nandi, N.; Sardar, A.H.; Das, S.; Kumar, S.; Pandey, K.; Ravidas, V.; Kumar, M.; De, T.; et al. Mechanism of
amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 2012, 56, 1031–1041. [CrossRef]
[PubMed]
40. Pramanik, P.K.; Alam, M.N.; Roy Chowdhury, D.; Chakraborti, T. Drug Resistance in Protozoan Parasites: An Incessant Wrestle
for Survival. J. Glob. Antimicrob. Resist. 2019, 18, 1–11. [CrossRef]
41. Muriithi, W.; Macharia, L.W.; Heming, C.P.; Echevarria, J.L.; Nyachieo, A.; Filho, P.N.; Neto, V.M. ABC transporters and the
hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol. Med. 2020, 17, 253–269. [CrossRef]
42. Leprohon, P.; Legare, D.; Ouellette, M. Intracellular localization of the ABCC proteins of Leishmania and their role in resistance to
antimonials. Antimicrob. Agents Chemother. 2009, 53, 2646–2649. [CrossRef] [PubMed]
43. Messaritakis, I.; Christodoulou, V.; Mazeris, A.; Koutala, E.; Vlahou, A.; Papadogiorgaki, S.; Antoniou, M. Drug resistance in
natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression. PLoS ONE 2013, 8, e65467. [CrossRef]
[PubMed]
44. Coelho, A.C.; Boisvert, S.; Mukherjee, A.; Leprohon, P.; Corbeil, J.; Ouellette, M. Multiple mutations in heterogeneous miltefosine-
resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl. Trop. Dis. 2012, 6, e1512.
[CrossRef]
45. BoseDasgupta, S.; Ganguly, A.; Roy, A.; Mukherjee, T.; Majumder, H.K. A novel ATP-binding cassette transporter, ABCG6 is
involved in chemoresistance of Leishmania. Mol. Biochem. Parasitol. 2008, 158, 176–188. [CrossRef]
46. El Fadili, K.; Messier, N.; Leprohon, P.; Roy, G.; Guimond, C.; Trudel, N.; Saravia, N.G.; Papadopoulou, B.; Legare, D.; Ouellette,
M. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes.
Antimicrob. Agents Chemother. 2005, 49, 1988–1993. [CrossRef] [PubMed]
47. Moreira, D.S.; Monte Neto, R.L.; Andrade, J.M.; Santi, A.M.; Reis, P.G.; Frezard, F.; Murta, S.M. Molecular characterization of the
MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony. Int. J. Parasitol.
Drugs Drug Resist. 2013, 3, 143–153. [CrossRef] [PubMed]
48. Castanys-Munoz, E.; Alder-Baerens, N.; Pomorski, T.; Gamarro, F.; Castanys, S. A novel ATP-binding cassette transporter from
Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol. Microbiol.
2007, 64, 1141–1153. [CrossRef]
Microorganisms 2021, 9, 1408 15 of 15
49. Castanys-Munoz, E.; Perez-Victoria, J.M.; Gamarro, F.; Castanys, S. Characterization of an ABCG-like transporter from the
protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob. Agents Chemother.
2008, 52, 3573–3579. [CrossRef] [PubMed]
50. Lachaud, L.; Bourgeois, N.; Plourde, M.; Leprohon, P.; Bastien, P.; Ouellette, M. Parasite susceptibility to amphotericin B in
failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin. Infect. Dis.
2009, 48, e16–e22. [CrossRef]
51. Van den Kerkhof, M.; Mabille, D.; Hendrickx, S.; Leprohon, P.; Mowbray, C.E.; Braillard, S.; Ouellette, M.; Maes, L.; Caljon, G.
Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance. Antimicrob. Agents
Chemother. 2020, 64. [CrossRef]
52. Ryan, K.A.; Dasgupta, S.; Beverley, S.M. Shuttle cosmid vectors for the trypanosomatid parasite Leishmania. Gene 1993,
131, 145–150. [CrossRef]
53. Potvin, J.E.; Leprohon, P.; Gazanion, E.; Sharma, M.; Fernandez-Prada, C.; Ouellette, M. Cos-Seq: A High-Throughput Gain-of-
Function Screen for Drug Resistance Studies in Leishmania. Methods Mol. Biol. 2019, 1971, 141–167. [CrossRef] [PubMed]
54. Steketee, P.C.; Vincent, I.M.; Achcar, F.; Giordani, F.; Kim, D.H.; Creek, D.J.; Freund, Y.; Jacobs, R.; Rattigan, K.; Horn, D.; et al.
Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei. PLoS Negl. Trop. Dis. 2018,
12, e0006450. [CrossRef]
55. Barrand, M.A.; Bagrij, T.; Neo, S.Y. Multidrug resistance-associated protein: A protein distinct from P-glycoprotein involved in
cytotoxic drug expulsion. Gen. Pharmacol. 1997, 28, 639–645. [CrossRef]
56. Chauhan, I.S.; Rao, G.S.; Singh, N. Enhancing the copy number of Ldrab6 gene in Leishmania donovani parasites mediates
drug resistance through drug-thiol conjugate dependent multidrug resistance protein A (MRPA). Acta Trop. 2019, 199, 105158.
[CrossRef]
57. Kaur, J.; Dey, C.S. Putative P-glycoprotein expression in arsenite-resistant Leishmania donovani down-regulated by verapamil.
Biochem. Biophys Res. Commun. 2000, 271, 615–619. [CrossRef]
58. Bellamy, W.T. P-glycoproteins and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 161–183. [CrossRef]
59. Gupta, I.; Aggarwal, S.; Singh, K.; Yadav, A.; Khan, S. Ubiquitin Proteasome pathway proteins as potential drug targets in parasite
Trypanosoma cruzi. Sci. Rep. 2018, 8, 8399. [CrossRef] [PubMed]
60. Bibo-Verdugo, B.; Jiang, Z.; Caffrey, C.R.; O’Donoghue, A.J. Targeting proteasomes in infectious organisms to combat disease.
FEBS J. 2017, 284, 1503–1517. [CrossRef] [PubMed]
61. Gannavaram, S.; Sharma, P.; Duncan, R.C.; Salotra, P.; Nakhasi, H.L. Mitochondrial associated ubiquitin fold modifier-1 mediated
protein conjugation in Leishmania donovani. PLoS ONE 2011, 6, e16156. [CrossRef] [PubMed]
62. Li, Y.; Li, Z.; Wang, C.C. Differentiation of Trypanosoma brucei may be stage non-specific and does not require progression of cell
cycle. Mol. Microbiol. 2003, 49, 251–265. [CrossRef] [PubMed]
63. Damianou, A.; Burge, R.J.; Catta-Preta, C.M.C.; Geoghegan, V.; Nievas, Y.R.; Newling, K.; Brown, E.; Burchmore, R.; Rodenko, B.;
Mottram, J.C. Essential roles for deubiquitination in Leishmania life cycle progression. PLoS Pathog. 2020, 16, e1008455. [CrossRef]
64. Tan, J.; Jakob, U.; Bardwell, J.C. Overexpression of two different GTPases rescues a null mutation in a heat-induced rRNA
methyltransferase. J. Bacteriol. 2002, 184, 2692–2698. [CrossRef]
65. Bocchetta, M.; Xiong, L.; Mankin, A.S. 23S rRNA positions essential for tRNA binding in ribosomal functional sites. Proc. Natl.
Acad. Sci. USA 1998, 95, 3525–3530. [CrossRef]
66. Sacerdoti-Sierra, N.; Jaffe, C.L. Release of ecto-protein kinases by the protozoan parasite Leishmania major. J. Biol. Chem. 1997,
272, 30760–30765. [CrossRef]
67. Bhatia, A.; Sanyal, R.; Paramchuk, W.; Gedamu, L. Isolation, characterization and disruption of the casein kinase II alpha subunit
gene of Leishmania chagasi. Mol. Biochem. Parasitol. 1998, 92, 195–206. [CrossRef]
68. Krober-Boncardo, C.; Lorenzen, S.; Brinker, C.; Clos, J. Casein kinase 1.2 over expression restores stress resistance to Leishmania
donovani HSP23 null mutants. Sci. Rep. 2020, 10, 15969. [CrossRef] [PubMed]
69. Sindhe, K.M.V.; Wu, W.; Legac, J.; Zhang, Y.K.; Easom, E.E.; Cooper, R.A.; Plattner, J.J.; Freund, Y.R.; DeRisi, J.L.; Rosenthal, P.J.
Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination
or Sumoylation. mBio 2020, 11. [CrossRef]
